Category: Hepatitis

Spring update from PHCN

This last month has been a whirlwind of symposiums, conferences and meetings.  We learned and shared a lot during our time spent with colleagues and collaborators across the country.  At the PAN ‘Effective Interventions’ conference in Vancouver, we presented on the benefits of the Community Readiness Model.   In Toronto, we presented about the patient experience… Read more »

CATIE’s HepCInfo Update 5.1

New and Noteworthy Montreal study shows testing positive for hepatitis C linked to decreased injection drug use People who inject drugs and who test positive for hepatitis C were more likely to decrease their drug use then people who tested negative, reported researchers in Clinical Infectious Diseases. From 2004 to 2011, the University of Montreal… Read more »

From CATIE: Top 10 HIV and Hep C Research News from 2013

Original posted on CATIE. Top 10 HIV and Hep C Research News from 2013 What were the most notable HIV and hepatitis C research stories from 2013? We’ve listed the top 10 stories from CATIE News below.   1. New evidence-based approaches to HIV and hepatitis C From national guidelines for HIV testing to best… Read more »

Dec 23, 2013 03:06 pm | Deb Schmitz   Recent comments by Liberal MP Gerry Byrne regarding Pamela Anderson show the depth of stigma and misinformation about hepatitis C that still exists in Canada today. President of Pacific Hepatitis C Network and hepatitis C survivor Daryl Luster states, “Stigma related to hepatitis C, and the… Read more »

February 26 – 28, 2014, Richmond, BC  Registration Deadline: Friday, January 24th @4:00pm The Pacific AIDS Network (PAN) is excited to announce that we will be hosting a two and a half day conference for PAN member organizations and other allied/partner organizations, where frontline prevention, education, harm reduction, health promotion workers and program managers and… Read more »

CATIE’s HepCinfo Update 4.24

Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:”Table Normal”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:””; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”;} New and Noteworthy New study estimates cases of hepatitis B and C, but experts warn figures may be too low A new federal government… Read more »

CATIE HepCinfo Update 4.22

New and Noteworthy FDA advisory committee recommends the approval of simeprevir and sofosbuvir The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously recommended the approval of two direct-acting antivirals for hepatitis C, simeprevir and sofosbuvir. The newer direct-acting antiviral medications are more effective, easier to take and have significantly fewer… Read more »